Brooks Laboratories Limited (NSE:BROOKS)

India flag India · Delayed Price · Currency is INR
58.46
-2.54 (-4.16%)
Mar 9, 2026, 3:29 PM IST
Market Cap1.80B -57.9%
Revenue (ttm)888.46M +15.4%
Net Income216.03M
EPS7.40
Shares Out29.46M
PE Ratio8.24
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,170
Average Volume107,044
Open61.00
Previous Close61.00
Day's Range57.25 - 61.00
52-Week Range58.14 - 164.02
Beta0.42
RSI28.65
Earnings DateMay 18, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ... [Read more]

Sector Healthcare
Founded 2002
Employees 323
Stock Exchange National Stock Exchange of India
Ticker Symbol BROOKS
Full Company Profile

Financial Performance

In fiscal year 2025, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2024.

Financial Statements